Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
09 2019
Historique:
received: 29 01 2019
accepted: 12 03 2019
pubmed: 29 5 2019
medline: 17 7 2020
entrez: 29 5 2019
Statut: ppublish

Résumé

Graft-versus-host disease (GVHD) is a major cause of transplant-related mortality (TRM) after allogeneic haematopoietic stem cell transplantation (HSCT) and presents a challenge in haploidentical HSCT. GVHD may be prevented by ex vivo graft T-cell depletion or in vivo depletion of proliferating lymphocytes. However, both approaches pose significant risks, particularly infections and relapse, compromising survival. A photodepletion strategy to eliminate alloreactive T cells from mismatched donor lymphocyte infusions (enabling administration without immunosuppression), was used to develop ATIR101, an adjunctive therapy for use after haploidentical HSCT. In this phase I dose-finding study, 19 adults (median age: 54 years) with high-risk haematological malignancies were treated with T-cell-depleted human leucocyte antigen-haploidentical myeloablative HSCT followed by ATIR101 at doses of 1 × 10

Identifiants

pubmed: 31135970
doi: 10.1111/bjh.15970
pmc: PMC6771482
doi:

Banques de données

ClinicalTrials.gov
['NCT00993486']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

754-766

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Références

Semin Oncol. 2012 Dec;39(6):674-82
pubmed: 23206844
Blood. 2004 Feb 1;103(3):767-76
pubmed: 12958064
Biol Blood Marrow Transplant. 2018 May;24(5):895-908
pubmed: 29339270
Bone Marrow Transplant. 2013 Mar;48(3):346-50
pubmed: 22863723
Semin Hematol. 2016 Oct;53(4):252-256
pubmed: 27788763
Bone Marrow Transplant. 2003 Jan;31(1):39-44
pubmed: 12621505
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Immunol Today. 1998 Feb;19(2):69-74
pubmed: 9509761
Front Immunol. 2016 Nov 17;7:507
pubmed: 27909435
Blood. 2006 Sep 15;108(6):1797-808
pubmed: 16741253
Blood. 2014 Jul 24;124(4):638-44
pubmed: 24923299
Transplantation. 1999 Jan 15;67(1):124-30
pubmed: 9921808
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Haematologica. 2015 May;100(5):683-9
pubmed: 25769546
N Engl J Med. 1998 Oct 22;339(17):1186-93
pubmed: 9780338
Lancet. 2002 Jul 13;360(9327):130-7
pubmed: 12126823
J Exp Med. 2008 Mar 17;205(3):711-23
pubmed: 18332179
Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8
pubmed: 20800103
Blood. 2010 Dec 2;116(23):4859-69
pubmed: 20798236
Blood. 2011 Jul 14;118(2):282-8
pubmed: 21527516
Blood. 2015 Jun 25;125(26):4103-13
pubmed: 25977584
Bone Marrow Transplant. 2018 Sep;53(9):1139-1148
pubmed: 29540849
Cancer Treat Rev. 2010 Nov;36(7):528-38
pubmed: 20381970
Bone Marrow Transplant. 2010 May;45(5):807-10
pubmed: 20190834
Blood Adv. 2018 Feb 13;2(3):299-307
pubmed: 29440002
Blood. 1998 Jul 1;92(1):101-7
pubmed: 9639505
Blood. 2017 Aug 3;130(5):677-685
pubmed: 28588018
Blood. 2011 Oct 27;118(17):4732-9
pubmed: 21868572
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
Blood. 2007 Sep 1;110(5):1689-97
pubmed: 17478639
Blood. 2002 Jul 15;100(2):375-82
pubmed: 12091325
Leukemia. 2015 Sep;29(9):1891-900
pubmed: 25882700
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Science. 1999 Oct 29;286(5441):958-61
pubmed: 10542151
J Clin Oncol. 2017 Sep 10;35(26):3002-3009
pubmed: 28644773
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
Bone Marrow Transplant. 2016 Jul;51(7):915-8
pubmed: 27088377
J Immunol. 2010 Jun 15;184(12):6739-45
pubmed: 20483749
Blood. 2012 Mar 1;119(9):1972-80
pubmed: 22210876
Blood. 2015 Aug 20;126(8):1033-40
pubmed: 26130705
Blood. 2013 Jan 31;121(5):752-8
pubmed: 23223509
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
pubmed: 18489989
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Blood. 2002 May 1;99(9):3083-8
pubmed: 11964269
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):76-83
pubmed: 17977031
J Clin Invest. 2003 Jul;112(1):101-8
pubmed: 12840064
Biol Blood Marrow Transplant. 2011 May;17(5):591-7
pubmed: 20732435
Lancet Oncol. 2009 May;10(5):489-500
pubmed: 19345145
Bone Marrow Transplant. 2015 Aug;50(8):1037-56
pubmed: 25798672
Blood. 2008 Apr 15;111(8):4392-402
pubmed: 17878399

Auteurs

Denis Claude Roy (DC)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Sylvie Lachance (S)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Sandra Cohen (S)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Jean-Sébastien Delisle (JS)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Thomas Kiss (T)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Guy Sauvageau (G)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Lambert Busque (L)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Imran Ahmad (I)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Lea Bernard (L)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Nadia Bambace (N)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Radia S Boumédine (RS)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.

Marie-Claude Guertin (MC)

Department of Biostatistics, Montreal Health Innovations Coordinating Center, Montreal, Canada.

Katayoun Rezvani (K)

Department of Stem Cell Transplant and Cellular Therapy, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA.

Stephan Mielke (S)

Department of Internal Medicine II, Center of Allogeneic Stem Cell Transplantation, Wuerzburg University Medical Center, University of Wuerzburg, Wuerzburg, Germany.
Department of Laboratory Medicine, CAST, Karolinska Institute and University Hospital, Stockholm, Sweden.

Claude Perreault (C)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Jean Roy (J)

Division of Hematology-Oncology/Stem Cell Transplantation, Hôpital Maisonneuve-Rosemont Research Center, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH